Literature DB >> 20156329

Hourly measurements not required for safe and effective glycemic control in the critically ill patient.

Miriam Hoekstra, Mathijs Vogelzang, Evgeny Verbitskiy, Maarten W Nijsten.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20156329      PMCID: PMC2875483          DOI: 10.1186/cc8190

Source DB:  PubMed          Journal:  Crit Care        ISSN: 1364-8535            Impact factor:   9.097


× No keyword cloud information.

In the recently published work of Juneja and colleagues the authors describe the excellent results of a computerized insulin dosing algorithm (Clarian GlucoStabilizer™) [1]. To prevent hypoglycemia, however, the authors note that frequent (that is, hourly) measurements are required. We believe that, with an adequate algorithm, the required level of glucose control can be reached without hourly glucose measurements. We implemented the glucose regulation for intensive care patients (GRIP) computer-assisted glucose regulation program, which uses time-variant sampling intervals [2]. In a recent analysis, hypoglycemia rates were comparable with or lower than those described by Juneja and colleagues [3]. Most importantly, these rates were achieved with only 5.6 measurements per patient per day. In all fairness it must be said that GRIP aimed at (and achieved) levels of 4.0 to 7.5 mmol/l, which is not as tight and challenging as the GlucoStabilizer™ target of 4.4 to 6.1 mmol/l. Nevertheless, it is our conviction that an up to fivefold higher glucose sampling rate cannot be justified by current evidence on glucose control. Finally, we would like to note that two main approaches for designing computer control of glucose levels exist: model predictive control, and proportional-integral derivative [4]. The underlying algorithm of GRIP is not model predictive control, as mistakenly stated in the article by Juneja and colleagues [1], but proportional-integral derivative. In fact, the algorithm of Juneja and colleagues also appears to be proportional-integral derivative. To achieve effective and safe computerized glucose control, therefore, it is not necessary to perform hourly measurements, provided a realistic target and an adequate algorithm with a time-variant sampling rate are used.

Abbreviations

GRIP: glucose regulation for intensive care patients.

Competing interests

The work of EV on glucose regulation in the intensive care unit is supported by the Netherlands Science Organization through the national cluster Non-linear Dynamics of Natural Systems. MH, MV and MWN declare that they have no competing interests; in particular not with regard to GRIP, which is an open source application.
  3 in total

Review 1.  Health technology assessment review: Computerized glucose regulation in the intensive care unit--how to create artificial control.

Authors:  Miriam Hoekstra; Mathijs Vogelzang; Evgeny Verbitskiy; Maarten W N Nijsten
Journal:  Crit Care       Date:  2009-10-16       Impact factor: 9.097

2.  Computerized intensive insulin dosing can mitigate hypoglycemia and achieve tight glycemic control when glucose measurement is performed frequently and on time.

Authors:  Rattan Juneja; Corbin P Roudebush; Stanley A Nasraway; Adam A Golas; Judith Jacobi; Joni Carroll; Deborah Nelson; Victor J Abad; Samuel J Flanders
Journal:  Crit Care       Date:  2009-10-12       Impact factor: 9.097

3.  Computer-assisted glucose control in critically ill patients.

Authors:  Mathijs Vogelzang; Bert G Loef; Joost G Regtien; Iwan C C van der Horst; Hein van Assen; Felix Zijlstra; Maarten W N Nijsten
Journal:  Intensive Care Med       Date:  2008-04-04       Impact factor: 17.440

  3 in total
  1 in total

1.  Trial design: Computer guided normal-low versus normal-high potassium control in critically ill patients: Rationale of the GRIP-COMPASS study.

Authors:  Miriam Hoekstra; Mathijs Vogelzang; Iwan Cc van der Horst; Annemieke Oude Lansink; Joost Maa van der Maaten; Farouq Ismael; Felix Zijlstra; Maarten Wn Nijsten
Journal:  BMC Anesthesiol       Date:  2010-12-31       Impact factor: 2.217

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.